January 30, 2004Clinical Endocrinology
Effects of conjugated oestrogen and droloxifene on the renin–angiotensin system, blood pressure and renal blood flow in postmenopausal women
Key result
Both conjugated equine oestrogen and droloxifene significantly increased plasma immunoreactive angiotensin II levels compared to baseline in normotensive (P<0.002) and hypertensive (P<0.005) women.
Why the study?
Do conjugated equine oestrogen and droloxifene alter RAAS components and blood pressure in postmenopausal women?
Population
31 postmenopausal women (21 normotensive and 10 hypertensive)
Comparison
Conjugated equine oestrogen 0.625 mg/day or… vs Alternate medication and baseline
Design
Other
Follow-up
6 weeks per treatment
Authors
Discussion
Loading...
Member takes
Implication
Dissociates angiotensin II elevation from blood pressure change; extends RAAS modulation data for these agents in postmenopausal women.
Structured PICO
Do conjugated equine oestrogen and droloxifene alter RAAS components and blood pressure in postmenopausal women?
P
Population
31 normotensive and hypertensive postmenopausal women treated with conjugated equine oestrogen and droloxifene in a crossover design for 6 weeks per treatment.
I
Intervention
Conjugated equine oestrogen (CEE) 0.625 mg/day or droloxifene 60 mg/day for 6 weeks
C
Comparator
Alternate medication (crossover design with 4-week washout) and baseline
O
Outcome
Individual components of renin-angiotensin-aldosterone system (RAAS) and blood pressuresurrogate
Main Result
p-value: p=<0.002
Both conjugated equine oestrogen and droloxifene increase circulating levels of immunoreactive angiotensin II in postmenopausal women without altering systemic blood pressure.
Cite This Study
Seely et al. (2004) studied Postmenopausal women (normotensive and hypertensive) (n=31). Conjugated equine oestrogen (CEE) and droloxifene vs. Baseline was evaluated on Plasma immunoreactive angiotensin II levels (p=<0.002). Both conjugated equine oestrogen and droloxifene significantly increased plasma immunoreactive angiotensin II levels compared to baseline in normotensive (P<0.002) and hypertensive (P<0.005) women.